Trials / Completed
CompletedNCT00511524
An Imaging Study to Investigate the Distribution of GW842166X in the Brain.
An Open Label Positron Emission Tomography (PET) Study to Investigate Brain Penetration by [11C]GW842166 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
GW842166X is being developed for the treatment and management of inflammatory pain. GW842166X is a CB2 receptor agonist and the mechanism is not fully understood, although it is thought that for the anti-inflammatory action the drug is required to cross inot the brain from the blood. This study aims to look at if the drug crosses into the brain once given orally using an imaging technique called positron emission tomography.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW842166X | GW842166X will available with dose strength of 100 mg capsules. Four 100mg GW842166X capsules will be used for the 400 mg oral dose of GW842166X. |
| DRUG | [carbonyl-^11C]GW842166 | \[carbonyl-\^11C\]GW842166 will b available as Intravenous solution. |
Timeline
- Start date
- 2007-06-26
- Primary completion
- 2007-07-04
- Completion
- 2007-07-04
- First posted
- 2007-08-06
- Last updated
- 2017-08-07
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT00511524. Inclusion in this directory is not an endorsement.